1. 1. Identification and evaluation of biomarkers for chronic aging-related diseases (fatty liver disease, type 2 diabetes, cardiovascular, cognitive impairment, dementia) and disease progression;
   2. Investigations of high-dimensional data (genome-wide association studies, metabolomics and proteomics) in observational epidemiology;
   3. Advancement of methodological approaches for the epidemiological investigation of biomarkers in chronic diseases (Mendelian Randomization, pathway analyses, and layering of high-dimensional data).

   Part of researchteam funded by the Novo Nordisk Foundation Challenge Grant for the research project titled “Harnessing the Power of Big Data to Address the Societal Challenge of Ageing”.  Aiming to combine data repositories and tissue biobank from millions of Danes to estimate prognosis and reclassify (biopsy-proven) diseases. https://www.dataforgood.science

   At Harvard T. H. Chan I lead projects funded by the American Diabetes Association, the Bright Focus Foundation, and NIH to investigate plasma biomarkers in relation to diabetes, CVD, cognitive impairment and risk of dementia. Investigations are conducted in the Multi-Ethnic Study of Atherosclerosis, the Cardiovascular Health Study, and the Gingko Evaluation of Memory Study.

EDUCATION (list in chronological order, beginning with most recent):

2008 PhD, Epidemiology, Aarhus University, Denmark

2005 MSc, Public Health Science, University of Copenhagen, Denmark

OTHER ACADEMIC APPOINTMENTS (list in chronological order, beginning with most recent):

Instructor, Cardiovascular Epidemiology (EPI223) for MSc and doctoral students; Harvard T. H. Chan. Annually 2012-2020.

Lecturer, Mendelian Randomization and genome-wide association studies for MSc and doctoral students at Harvard T. H. Chan School of Public Health.

Instructor, Epidemiology for medical students, University of Copenhagen. Bi-annual course. 2020-

Updated list of publications can be found by clicking here

Novo Nordisk A/S: 6 month salary for PhD student to work on fatty liver in the pathology registry (2023). 

Consultant for Pfizer A/S on register-based research (2023).